ABIVAX news, videos and press releases
For more news please use our advanced search feature.
ABIVAX - More news...
ABIVAX - More news...
- EQS-News: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
- Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
- EQS-News: Abivax presents third quarter 2024 key financial information
- Abivax presents third quarter 2024 key financial information
- EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
- Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
- ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.
- EQS-News: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
- Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
- EQS-News: Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
- Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
- Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
- EQS-News: Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
- EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
- Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
- EQS-News: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
- Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
- EQS-News: Abivax presents first-half 2024 financial results
- Abivax presents first-half 2024 financial results
- EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
- Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
- EQS-News: Abivax Provides Operational and Key Program Update
- Abivax Provides Operational and Key Program Update
- Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
- Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
- Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
- EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
- EQS-News: Abivax reports 2023 financial results and operational update
- EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
- Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
